» Articles » PMID: 39780938

A Systematic Review Uncovering Modifiable Influences on Statin Adherence

Overview
Date 2025 Jan 9
PMID 39780938
Authors
Affiliations
Soon will be listed here.
Abstract

Statins are effective in reducing cardiovascular disease (CVD) risk, but adherence rates remain low globally. Understanding and addressing modifiable influences on adherence is key to improving outcomes. Existing reviews have methodological limitations, often failing to integrate qualitative and quantitative data or consider specific barriers to statin adherence. This systematic review aimed to identify modifiable barriers and facilitators to statin adherence using the Theoretical Domains Framework (TDF). A comprehensive search of Embase, MEDLINE, PsycINFO, and CINAHL was conducted, covering studies from January 1998 to November 2023. Data were coded to TDF domains and synthesized to identify specific influences on adherence. The nature of the evidence (qualitative or quantitative) was recorded for each influence, and variations among patient groups were noted. Seventy studies from 20 countries were included, with only one focused on ethnic minorities. The most commonly identified domains affecting adherence were "Beliefs about Consequences", "Knowledge", 'Environmental Context and Resources', and "Social Influences". Key factors included knowledge of disease, perceived disease threat, perceived benefits of statins, and patient-provider communication and trust. While side effects had inconsistent associations with adherence, forgetfulness was mainly addressed in quantitative studies, and social influences were highlighted in qualitative research. This review identified modifiable factors that could improve statin adherence. Future research should focus on addressing barriers faced by underrepresented groups to create more inclusive and effective interventions that enhance patient support and communication for better health outcomes.

Citing Articles

Letter to the editor "Patterns and predictors of statin therapy after ischemic stroke and TIA: Insights from the LIPYDS multicentre study".

Fatima S Neurol Sci. 2025; .

PMID: 39934581 DOI: 10.1007/s10072-025-08049-2.

References
1.
Stewart S, Moon Z, Horne R . Medication nonadherence: health impact, prevalence, correlates and interventions. Psychol Health. 2022; 38(6):726-765. DOI: 10.1080/08870446.2022.2144923. View

2.
Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W . The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Ann Behav Med. 2013; 46(1):81-95. DOI: 10.1007/s12160-013-9486-6. View

3.
Lam W, Fresco P . Medication Adherence Measures: An Overview. Biomed Res Int. 2015; 2015:217047. PMC: 4619779. DOI: 10.1155/2015/217047. View

4.
Lemstra M, Blackburn D, Crawley A, Fung R . Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012; 28(5):574-80. DOI: 10.1016/j.cjca.2012.05.007. View

5.
Haddad C, Hallit S, Salhab M, Hajj A, Sarkis A, Ayoub E . Association Between Adherence to Statins, Illness Perception, Treatment Satisfaction, and Quality of Life among Lebanese patients. J Cardiovasc Pharmacol Ther. 2018; 23(5):414-422. DOI: 10.1177/1074248418769635. View